Australia markets closed

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5750+0.0950 (+6.40%)
As of 11:39AM EDT. Market open.
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
146,033
146,033
157,074
209,819
108,085
Cost of revenue
4,942
4,942
5,213
3,402
2,705
Gross profit
141,091
141,091
151,861
206,417
105,380
Operating expenses
Research development
138,750
138,750
148,662
160,842
150,813
Selling general and administrative
131,881
131,881
145,401
143,846
126,417
Total operating expenses
270,631
270,631
294,063
304,688
277,230
Operating income or loss
-129,540
-129,540
-142,202
-98,271
-171,850
Interest expense
23,823
23,823
24,996
26,046
27,140
Total other income/expenses net
-356
-356
-83
-85
206
Income before tax
-142,776
-142,776
-164,922
-123,820
-195,964
Income tax expense
323
323
369
268
309
Income from continuing operations
-143,099
-143,099
-165,291
-124,088
-196,273
Net income
-143,099
-143,099
-165,291
-124,088
-196,273
Net income available to common shareholders
-143,099
-143,099
-165,291
-124,088
-196,273
Basic EPS
-1.31
-1.25
-2.02
-1.65
-2.72
Diluted EPS
-1.31
-1.25
-2.02
-1.65
-2.72
Basic average shares
108,031
114,221
81,871
75,218
72,044
Diluted average shares
108,031
114,221
81,871
75,218
72,044